Synonym: Ethyl (S)-11,12,13,13a-Tetrahydro-7-methoxy-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate; L-655708
CAS Number: 130477-52-0
Empirical Formula (Hill Notation): C18H19N3O4
Molecular Weight: 341.36
MDL Number: MFCD02684528
Linear Formula: C18H19N3O4
Product Type: Chemical
This picture is provided solely for illustration purposes, it may have been created or edited with AI. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material.
This image depicts L9787-5MG.
| assay |
≥98% (HPLC) |
| form |
powder |
| InChI |
1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3/t14-/m0/s1 |
| InChI key |
YKYOQIXTECBVBB-AWEZNQCLSA-N |
| originator |
Merck & Co., Inc., Kenilworth, NJ, U.S. |
| Quality Level |
100  |
| SMILES string |
CCOC(=O)c1ncn2-c3ccc(OC)cc3C(=O)N4CCCC4c12 |
| solubility |
DMSO: ≥6.0 mg/mL (Warmed) |
| |
H2O: insoluble |
| Application: |
L-655,708 has been used as an α5 GABAA receptor inverse agonist to inhibit the discriminative stimulus of propofol in a dose-dependent manner. |
| Biochem/physiol Actions: |
L-655,708 is an inverse agonist of the α5 γ-Aminobutyric acid type A (GABAA) receptor. It has an ability to increase cognition in rats. |
| Biochem/physiol Actions: |
Ligand for benzodiazepine site of GABAA receptors containing α5 subunits. |
| Biochem/physiol Actions: |
Novel ligand selective for the benzodiazepine site of GABAA receptors which contain the α5 subunit. |
| Features and Benefits: |
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Features and Benefits: |
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: |
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S. . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: |
5, 25 mg in glass bottle |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥98% (HPLC) |
| UNSPSC |
12352200 |